Physician profile
Timothy P Korytko
NPI 1205050739
$91,318.04
in general payments reported to CMS, 2019-2025
20 companies · $26K in 2025
The $26K reported for 2025 was more than what 98% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,990 · 2020: $5,708 · 2021: $8,345 · 2022: $25K · 2023: $13K · 2024: $8,335 · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $41K · Travel and Lodging: $4,564 · Food and Beverage: $2,108 · Consulting Fee: $356.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $40,500.00 |
| Travel and Lodging | $4,563.81 |
| Food and Beverage | $2,108.11 |
| Consulting Fee | $356.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $77,720.82 | 2019-2025 | Imfinzi, Tagrisso |
| Genzyme Corporation | $5,090.70 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $3,476.51 | 2019-2020 | |
| Pfizer INC. | $1,733.20 | 2022-2024 | |
| Telix Pharmaceuticals | $1,562.38 | 2025 | Illuccix |
| Tersera Therapeutics LLC | $356.00 | 2023 | |
| Novartis Pharmaceuticals Corporation | $355.95 | 2022-2025 | |
| Novocure INC. | $307.28 | 2019-2025 | Optune Lua (Novottf-200t), Optune Gio |
| E.R. Squibb & Sons, L.L.C. | $145.77 | 2024 | Opdivo, Opdualag |
| Sirtex Medical INC | $141.08 | 2022-2025 | Sir-Spheres Microspheres |
| Ipsen Biopharmaceuticals, INC | $125.00 | 2019 | |
| Siemens Medical Solutions USA, INC. | $66.47 | 2024 | Edge |
| Foundation Medicine, INC. | $61.18 | 2020 | |
| Boston Scientific Corporation | $41.19 | 2022 | |
| Iovance Biotherapeutics, INC. | $23.69 | 2025 | Amtagvi |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $22.97 | 2025 | Enhertu |
| Myovant Sciences Gmbh | $22.92 | 2022 | |
| Beigene USA, INC. | $22.14 | 2023 | Brukinsa |
| Takeda Pharmaceuticals U.S.A., INC. | $22.01 | 2024 | Fruzaqla |
| Myriad Genetic Laboratories, INC. | $20.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Korytko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.